HIV-1 fitness and replication capacity: What are they and can they help in patient management?

Current Infectious Disease Reports

Volumn 5, Issue 1, 2003, Pages 77-84

  Maldarelli, Frank ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; PROTEIN INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS PROTEIN;

CLINICAL FEATURE; CLINICAL PRACTICE; ENZYME ASSAY; GENE MUTATION; GENETIC CODE; GENETIC VARIABILITY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MONOTHERAPY; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; REVIEW; VIRUS LOAD; VIRUS REPLICATION;

EID: 0344426568     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-003-0068-9     Document Type: Review

References (43)

1. Clavel F, Race E, Mammano F: HIV-1 drug resistance and viral fitness. Adv Pharmacol 2000, 49:41-66.
2. Nijhuis M, Deeks S, Boucher C: Implications of antiretroviral resistance on viral fitness. Curr Opin Infect Dis 2001, 14:23-28.
3. Quiñones-Mateu M, Arts EJ: HIV-1 fitness: implications for drug resistance, disease progression, and global epidemic evolution. In HIV-1 Sequence Compendium 2001. Los Alamos, NM: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory; 2001:134-170.
4. Coffin, JM, Hughes SH, Varmus HE: Retroviruses. Plainview, NY: Cold Spring Harbor Laboratory Press; 1997.
5. Bour S, Strebel K: HIV-1 accessory proteins: multifunctional components of a complex system. Adv Pharmacol 2000, 48:75-120.
6. Zhang YM, Imamichi H, Imamichi T, et al.: Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol 1997, 71:6662-6670.
7. Maree AF, Keulen W, Boucher CA, De Boer RJ: Estimating relative fitness in viral competition experiments. J Virol 2000, 74:11067-11072.
8. Rouzine IM, Rodrigo A, Coffin JM: Transition between stochastic evolution and deterministic evolution in the presence of selection: general theory and application to virology. Microbiol Mol Biol Rev 2001, 65:151-185.
9. Wodarz D, Nowak MA: Mathematical models of HIV-1pathogenesis and treatment. Bioessays 2002, 24:1178-1187.
10. Bonhoeffer S, Barbour AD, De Boer RJ: Procedures for reliable estimation of viral fitness from time-series data. Proc R Soc Lond Biol Sci 2002, 269:1887-1893.
11. Mammano F, Trouplin V, Zennou V, Clavel F: Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug. J Virol 2000, 74:8524-8531.
12. Kosalaraksa P, Kavlick MF, Maroun V, et al.: Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an In vitro competitive HIV-1 replication assay. J Virol 1999, 73:5356-6533.
13. Maeda Y, Venzon DJ, Mitsuya H: Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance. J Infect Dis 1998, 177:1207-1213.
14. Kellam P, Larder BA: Retroviral recombination can lead to linkage of reverse transcriptase mutations that confer increased zidovudine resistance. J Virol 1995, 69:669-674.
15. Lu J, Kuritzkes DR: A novel recombinant marker virus assay for comparing the relative fitness of hiv-1 reverse transcriptase variants. J Acquir Immune Defic Syndr 2001, 27:7-13.
16. Martinez-Picado J, Savara AV, Sutton L, D'Aquila RT: Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol 1999, 7:3744-3752.
17. Martinez-Picado J, Savara AV, Shi L, et al.: Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants. Virology 2000, 275:318-322.
18. Harrigan PR, Bloor S, Larder BA: Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro. J Virol 1998, 72:3773-3778.
19. Frost SD, Nijhuis M, Schuurman R, et al.: Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection. J Virol 2000, 74:6262-6268.
20. Quinones-Mateu ME, Tadele M, Parera M, et al.: Insertions in the reverse transcriptase increase both drug resistance and viral fitness in a human immunodeficiency virus type 1 isolate harboring the multi-nucleoside reverse transcriptase inhibitor resistance 69 insertion complex mutation. J Virol 2002, 76:10546-10552.
21. Archer RH, Dykes C, Gerondelis P, et al.: Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture. J Virol 2000, 74:8390-8401.
22. Dykes C, Fox K, Lloyd A, et al.: Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants. Virology 2001, 285:193-203.
23. Seman AL, Pewen WF, Fresh LF et al.: The replicative capacity of rhesus macaque peripheral blood mononuclear cells for simian immunodeficiency virus in vitro is predictive of the rate of progression to AIDS in vivo. J Gen Virol 2000, 81(Pt 10):2441-2449.
24. Newstein MC, Desrosiers RC: Effects of reverse-transcriptase mutations M184V and E89G on simian immunodeficiency virus in Rhesus monkeys. J Infect Dis 2001, 184:1262-1267.
25. Van Rompay KK, Matthews TB, Higgins J, et al.: Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase. J Virol 2002, 76:6083-6092.
26. Shibata R, Igarashi T, Haigwood N, et al.: Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 1999, 5:204-210.
27. Soderberg K, Denekamp L, Nikiforow S, et al.: A nucleotide substitution in the tRNA(Lys) primer binding site dramatically increases replication of recombinant simian immunodeficiency virus containing a human immunodeficiency virus type 1 reverse transcriptase. J Virol 2002, 76:5803-5806.
28. Ambrose Z, Hughes SH, Kewal-Ramani VN: A new reverse transcriptase-SHIV-1to study HIV-1 non-nucleoside reverse transcriptase inihibitor-resistance in pigtailed macaques. Antiviral Ther 2002, 7:S44.
29. Aldrovandi GM, Zack JA: Replication and pathogenicity of human immunodeficiency virus type 1 accessory gene mutants in SCID-hu mice. J Virol 1996, 70:1505-1511.
30. Stoddart CA, Liegler TJ, Mammano F, et al.: Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. Nat Med 2001, 7:712-718.
31. Penn ML, Myers M, Eckstein DA, et al.: Primary and recombinant HIV-1 type 1 strains resistant to protease inhibitors are pathogenic in mature human lymphoid tissues. AIDS Res Hum Retroviruses 2001, 17:517-523.
32. Picchio GR, Valdez H, Sabbe R, et al.: Altered viral fitness of HIV-1 following failure of protease inhibitor-based therapy. J Acquir Immune Defic Syndr 2000, 25:289-295.
33. Petropoulos CJ, Parkin NT, Limoli KL, et al.: A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000, 44:920-928.
34. Lennerstrand J, Hertogs K, Stammers DK, Larder BA: Correlation between viral resistance to zidovudine and resistance at the reverse transcriptase level for a panel of human immunodeficiency virus type 1 mutants. J Virol 2001, 75:7202-7205.
35. Gao HQ, Boyer PL, Sarafianos SG, et al.: The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase. J Mol Biol 2000, 300:403-418.
36. Iga M, Matsuda Z, Okayama A, et al.: Rapid phenotypic assay for human immunodeficiency virus type 1 protease using in vitro translation. J Virol Method 2002, 106:25-37.
37. Deeks SG, Wrin T, Liegler T, et al.: Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001, 344:472-480.
38. Nijhuis M, Schuurman R, dejong D, et al.: Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 1999, 13:2349-2359.
39. Mammano F, Petit C, Clavel F: Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J Virol 1998, 72:7632-7637.
40. Barbour JD, Wrin T, Grant RM, et al.: Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. J Virol 2002, 76:11104-11112.
41. Grant RM, Barbour JD, Wrin T, et al.: Transmission of Drug Resistant HIV-1 exhibiting lower replication capacity is associated with higher CD4 counts. Antiviral Ther 2002, 7:S41.
42. Brenner BG, Routy JP, Petrella M, et al.: Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol 2002, 76:1753-1761.
43. Lecossier D, Bouchonnet F, Schneider P, et al.: Discordant increases in CD4+ T cells in human immunodeficiency virus-infected patients experiencing virologic treatment failure: role of changes in thymic output and T cell death. J Infect Dis 2001, 183:1009-1016.